Get the Stockscreener App
1.52
3.80%
-0.06
After Hours:
1.51
-0.01
-0.66%
Pliant Therapeutics Inc Stock (PLRX) Latest News
Drug developers Pliant and Acelyrin adopt poison pill provisions to fend off activist investor - The Business Journals
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - The Malaysian Reserve
Pliant Therapeutics Signs Shareholder Rights Agreement -March 13, 2025 at 08:32 am EDT - Marketscreener.com
Pliant Therapeutics adopts shareholder rights plan - Investing.com India
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement to Protect Shareholder Interests - Nasdaq
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement - Bluefield Daily Telegraph
Pliant Therapeutics Shields Against Hostile Takeover with Strategic Rights Plan - StockTitan
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant ... - Bluefield Daily Telegraph
Pliant dives 49% as it abandons phase 2 trial of bexotegrast for IPF - MSN
Pliant Therapeutics (NASDAQ:PLRX) Cut to “Hold” at Leerink Partnrs - Defense World
Needham Downgrades Pliant Therapeutics (MUN:9PT) - Nasdaq
If You Don’t Bullish On Pliant Therapeutics Inc (NASDAQ: PLRX) Now, You’ll Regret Your Decision Later - Stocks Register
Pliant halts lung fibrosis trial amid safety concerns - The Pharma Letter
Pliant Therapeutics (NASDAQ:PLRX) Price Target Cut to $3.00 by Analysts at Royal Bank of Canada - Defense World
Pliant Therapeutics (NASDAQ:PLRX) Cut to Market Perform at Leerink Partners - MarketBeat
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims On Behalf Of Investors Of Pliant Therapeutics - MENAFN.COM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc- PLRX - PR Newswire
Leerink Partners Downgrades Pliant Therapeutics (PLRX) - MSN
Pliant Therapeutics stock tumbles amid IPF trial cancellation - MSN
Pliant Therapeutics Drops IPF Drug Trial After Review, Analyst Flags Uncertain Future - Benzinga India
Hold Rating on Pliant Therapeutics Amid Trial Discontinuation and Safety Concerns - TipRanks
Pliant downgraded at Stifel on bexotegrast trial discontinuation - MSN
Pliant stock downgraded at Stifel trial discontinuation (PLRX:NASDAQ) - Seeking Alpha
This Teleflex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Stifel Downgrades Pliant Therapeutics to Hold From Buy, Adjusts Price Target to $3 From $32 - Marketscreener.com
Needham Downgrades Pliant Therapeutics to Hold From Buy -March 04, 2025 at 08:28 am EST - Marketscreener.com
Pliant Therapeutics: Hold Rating Maintained Amid Trial Discontinuation and Adjusted Financial Outlook - TipRanks
RBC Cuts Price Target on Pliant Therapeutics to $3 From $4, Keeps Sector Perform, Speculative Risk - Marketscreener.com
Pliant Therapeutics Reports Q4 2024 Results and Updates - MSN
Pliant Therapeutics price target lowered to $1.50 from $4 at Citi - TipRanks
Citi cuts Pliant Therapeutics stock target to $1.50, maintains neutral By Investing.com - Investing.com Canada
Cautious Hold Rating on Pliant Therapeutics Amid Uncertainty Over Bexotegrast Trial and Financial Outlook - TipRanks
Citi cuts Pliant Therapeutics stock target to $1.50, maintains neutral - Investing.com India
Hold Rating on Pliant Therapeutics Amidst BEACON-IPF Study Discontinuation and Uncertainty in Pipeline Prioritization - TipRanks
Pliant Therapeutics reinstated with a Neutral at Cantor Fitzgerald - TipRanks
Cantor Fitzgerald reinstates Pliant Therapeutics stock with neutral rating - Investing.com India
Cantor Fitzgerald reinstates Pliant Therapeutics stock with neutral rating By Investing.com - Investing.com UK
Pliant Therapeutics (NASDAQ:PLRX) Lowered to “Hold” Rating by Stifel Nicolaus - Defense World
Pliant Therapeutics (NASDAQ:PLRX) Lowered to Market Perform Rating by Leerink Partners - Defense World
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis - GlobeNewswire
Pliant Therapeutics shares rise on better-than-expected Q4 earnings - Investing.com
Pliant Therapeutics shares rise on better-than-expected Q4 earnings By Investing.com - Investing.com Australia
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results - GlobeNewswire
Pliant's IPF Trial Halted on Safety Concerns: What's Next for Their $357M Pipeline? - StockTitan
Stifel cuts Pliant Therapeutics stock rating to hold, target to $3 By Investing.com - Investing.com South Africa
Pliant ends late-stage pulmonary fibrosis trial amid safety concerns - FirstWord Pharma
Leerink cuts Pliant Therapeutics stock rating after trial halt - Investing.com India
Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder - Benzinga India
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc.PLRX - PR Newswire
Leerink downgrades Pliant Therapeutics after trial discontinuation - TipRanks
Pliant Therapeutics Discontinues BEACON-IPF Phase 2b Trial For Bexotegrast In IPF Patients - Nasdaq
Pliant touches record low after scrapping trial of lung-disease drug - TradingView
PLRX stock touches 52-week low at $2 amid sharp annual decline - Investing.com India
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):